Clinical trial
ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to…
NCT00420888 · Active Biotech AB, Industry · Completed
Key facts
| NCT number | NCT00420888 |
|---|---|
| Title | ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma |
| Official title | A Randomized, Open-label, Multi-center, Phase II/III Study on Treatment With ABR-217620/Naptumomab Estafenatox Combined With IFN-alpha vs. IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma. |
| Lead sponsor | Active Biotech AB, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | ABR-217620/naptumomab estafenatox, IFN-alpha |
| Enrollment | 526 |
| Start date | Jan 1, 2007 |
| Primary completion | Jan 1, 2013 |
| Completion | Jan 1, 2013 |
| First posted | Jan 11, 2007 |
| Last update posted | Jul 22, 2015 |
| Countries | Bulgaria, Romania, Russia, Ukraine, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: